Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
508 - If exacerbation rates are provided in a publication with other details with which NNTs can be calculated, would PAAB allow us to promote the NNTs?
-
The NNT is the estimated average number of patients who need to be treated to prevent one additional bad outcome (e.g. death, hospitalization). An NNT which is calculated by the manufacturer may be included in the APS provided the published paper conveys a statistically significant improvement in the corresponding absolute risk reduction (with multiplicity adjustments performed when required to manage risk of type I error).
The number needed to treat is the mathematical inverse of the absolute risk reduction (i.e. 1 divided by the absolute risk reduction). Note that the absolute risk reduction is the control event rate minus the experimental event rate.
